![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Clover Biopharmaceuticals Starts COVID-19 Vaccine Trial in Australia
Clover Biopharmaceuticals Starts COVID-19 Vaccine Trial in Australia
![Australia_FlagonMap.gif](https://www.fdanews.com/ext/resources/test/Device_Images6/Australia_FlagonMap.gif?t=1586293712&width=430)
China’s Clover Biopharmaceuticals has initiated a phase 1 clinical trial of its COVID-19 vaccine candidate SCB-2019 in Australia.
The study will evaluate SCB-2019 with adjuvants from GlaxoSmithKline and Dynavax. It is expected to enroll 150 patients.
The company anticipates preliminary results from the trial in August and hopes to begin a global phase 2/3 trial by the end of the year.
Upcoming Events
-
21Oct